Xinjian Lin

Title: Xinjian Lin: Innovator in Cell-Targeted Cytotoxic Constructs

Introduction

Xinjian Lin is a prominent inventor based in La Jolla, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of targeted therapies for proliferative diseases such as cancer. With a total of 3 patents, Lin's work focuses on innovative approaches to enhance the efficacy of cytotoxic agents.

Latest Patents

Lin's latest patents include groundbreaking inventions related to cell-targeted cytotoxic constructs. One of his notable inventions is directed to cell-targeted cytotoxic agents, which include sortase serine protease constructs. This invention provides methods for targeted cell killing, specifically for the treatment of proliferative diseases like cancer. The exemplary embodiments of this invention utilize an R-spondin ligand to effectively target the cytotoxic agents for cell killing.

Another significant patent by Lin involves cell-targeted cytotoxic constructs that comprise a targeting polypeptide, a linking polypeptide, and a cytotoxic polypeptide. In this construct, the targeting polypeptide can be R-spondin1 (RSPO1), R-spondin2 (RSPO2), or yoked chorionic gonadotropin (YCG). The linking polypeptide includes sequences such as LPXT or NPXT, while the cytotoxic moiety may consist of an auristatin or a truncated serine protease. These constructs are designed for targeted cell killing, particularly in the context of treating proliferative diseases.

Career Highlights

Xinjian Lin is associated with the Research Development Foundation, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and other proliferative diseases.

Collaborations

Lin collaborates with esteemed colleagues, including Stephen B Howell and Xiying Shang, who contribute to his research endeavors and the development of his innovative constructs.

Conclusion

Xinjian Lin's contributions to the field of biotechnology, particularly in the area of cell-targeted cytotoxic constructs, highlight his role as a leading inventor. His innovative approaches have the potential to revolutionize treatment options for patients suffering from proliferative diseases.